XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Accounting Policies [Line Items]    
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [1] $ (20,569) $ 8,312
Foreign Currency Transaction Gain (Loss), Realized [2] 8,667 (2,699)
Other Nonoperating Gains (Losses) 410 806
Other (expense) income, net (11,492) 6,419
Realized gain (loss) on derivatives not designated as hedging instruments [1] $ (2,232) $ 2,050
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 60  
Weighted average shares outstanding — diluted 25,167,845 27,079,455
Net Income (Loss) Per Share Attributable to Cimpress plc [Line Items]    
Weighted average shares outstanding — basic 25,167,845 26,468,769
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)(2) 0 610,686 [3],[4]
Weighted average shares outstanding — diluted 25,167,845 27,079,455
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount [3] 1,224,628 187,649
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,055,377  
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 341,158 98,319
Foreign Exchange Forward [Member]    
Accounting Policies [Line Items]    
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net $ (20,569) $ 8,312
[1] Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized (losses) gains of $(2,232) and $2,050 for the three months ended September 30, 2024 and 2023, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
[2] Currency-related gains (losses), net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, during the three months ended September 30, 2023, we recognized gains of $1,936 on a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. We did not hold any cross-currency swap contracts that were designated as cash flow hedges during the current quarter. Refer to Note 4 for additional details regarding our cash flow hedges.
[3] In the periods in which a net loss is recognized, the impact of share options, PSUs, RSUs and warrants is excluded from shares used in computed diluted net loss per share as it is anti-dilutive.
[4] On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the three months ended September 30, 2024, the average market price of our ordinary shares was higher than the strike price of the warrants and the weighted average anti-dilutive effect of the warrants (anti-dilutive due to our net loss position) was 341,158. For the three months ended September 30, 2023, the average market price of our ordinary shares was higher than the strike price of the warrants, and the weighted average dilutive effect of the warrants was 98,319.